breakout, page-48

And I would add, what's the incentive for patients who so far don't know if they are resistant to existing drugs to start with them when ATC is in market. None.

ATC may be officially targeting the gap market where patients are resistant to existing drugs, but it has huge potential to become the primary and preferred drug, particularly given its safety profile to date.